23 Annual Report 2022 Professor Emeritus Allan Cripps AO PhD BSc (Hons) FAHSM FASM FAIMS FIBMS FCHSMMAICD | Non-Executive Director (appointed 23 January 2020) Professor Cripps is a distinguished academic, clinical scientist and health services leader, havingmade significant contributions in immunology, diagnostics, and health services delivery. From2005 to 2016, Professor Cripps was the Pro Vice Chancellor (Health) at GriffithUniversity and is currently a research professor at GriffithUniversity, leading theMucosal Immunology ResearchGroup within theMenzies Health InstituteQueensland. Professor Cripps had near 20 years’ experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research onmucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over $17million inGovernment and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health andMedical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the AustralasianCollege of Health ServiceManagement. In 2015 he was awarded theOrder of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation. Professor Cripps is a Non-Executive Director of Neurotech International Limited (ASX: NTI) and Independent Chair of the Children’s Health Research Alliance Board. He was previously Non‑Executive Director of Research Australia (2005 – 2012) and theGoldCoast Hospital and Health Services Board (2011 – 2017). Professor Cripps is a member of the Company’s Remuneration Committee and Audit & Risk Committee. Professor Cripps has not been a director of any other listed companies in the last three years. INTERESTS IN THE SHARES AND OPTIONS OF THE COMPANY AND RELATED BODIES CORPORATE As at the date of issuing this report, the interests of the current directors in the shares of the Company were: Ordinary Shares Options Dr Geoffrey Cumming 177,414 552,000 Mr Max Johnston 404,310 500,000 Mr Philip Powell 396,631 500,000 Professor Allan Cripps - 500,000 EXECUTIVE MANAGEMENT AND COMPANY SECRETARY Chief Executive Officer Dr Leearne Hinch BSc BVMS MBA Dr Hinch joined INOVIQas CEO in 2016 bringing over 20 years’ experience in the life sciences industry. She has held past leadership roles as a biotechnology executive and life sciences consultant at private and ASX-listed companies including Ingeneus Solutions, Eustralis Pharmaceuticals, OBJ andHolista Colltech, where she gained a track record leading all aspects of life sciences businesses including technical, operational, and strategic. Dr Hinch has spearheaded the development of corporate strategy and partnerships, M&A transactions and capital raisings, and delivered business growth and revenue targets. She has also led development and commercialisation teams for multiple diagnostic, device, therapeutic and animal health products. Dr Hinch holds a Bachelor of Science, Bachelor of VeterinaryMedicine and Surgery and aMaster of Business Administration. Chief Financial Officer and Company Secretary Mr Tony Di Pietro BCommCA AGIAMAICD (appointed 28 July 2020) Mr Di Pietro is a Chartered Accountant with significant corporate accounting experience, gained both in Australia and the UK. He holds a Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia and is a member of the Australian Institute of Company Directors. Tony is a finance executive with extensive technical accounting, corporate tax, and company secretarial experience. Mr Di Pietro has held senior roles within the Biotechnology/MedTech industry for the past 15 years including Sienna Cancer Diagnostics Ltd and Acrux Ltd. Tony played a significant role in the ASX listing of both Sienna and Acrux and the merger between Sienna and BARD1. He has also gained valuable experience in other industry sectors, employed by companies such as BHP Ltd, ExxonMobil Ltd, HSBC Ltd andWilson Group.
RkJQdWJsaXNoZXIy MjE2NDg3